Skip to main content


Fig. 4 | Radiation Oncology

Fig. 4

From: Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

Fig. 4

Subgroup analysis. a and b demonstrate the impact of Chua’s prognostic score on the overall survival of patients with intermediate and bad prognosis in the study group (p = 0.3) and the remaining group (p = 0.003). c and d illustrate the impact of the cetuximab-taxane scheme unaffected by the prognostic score. It shows improved survival, but significance could not be demonstrated, neither in patients with intermediate (p = 0.4) nor with bad prognosis (p = 0.08)

Back to article page